NASDAQ:DARE Daré Bioscience (DARE) Stock Price, News & Analysis → With revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radar (From Stocks News) (Ad) Free DARE Stock Alerts $0.36 +0.04 (+12.50%) (As of 05/15/2024 ET) Add Compare Share Share Today's Range$0.33▼$0.3950-Day Range$0.28▼$0.5552-Week Range$0.27▼$1.06Volume2.12 million shsAverage Volume574,615 shsMarket Capitalization$36.21 millionP/E RatioN/ADividend YieldN/APrice Target$4.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Daré Bioscience alerts: Email Address Daré Bioscience MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside1,150.0% Upside$4.50 Price TargetShort InterestHealthy0.29% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.34Based on 14 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.22) to $0.10 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.61 out of 5 starsMedical Sector740th out of 928 stocksPharmaceutical Preparations Industry347th out of 431 stocks 3.3 Analyst's Opinion Consensus RatingDaré Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDaré Bioscience has only been the subject of 2 research reports in the past 90 days.Read more about Daré Bioscience's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.29% of the outstanding shares of Daré Bioscience have been sold short.Short Interest Ratio / Days to CoverDaré Bioscience has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Daré Bioscience has recently increased by 17.58%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDaré Bioscience does not currently pay a dividend.Dividend GrowthDaré Bioscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DARE. Previous Next 2.4 News and Social Media Coverage News SentimentDaré Bioscience has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Daré Bioscience this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for DARE on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows7 people have added Daré Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Daré Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.30% of the stock of Daré Bioscience is held by insiders.Percentage Held by InstitutionsOnly 6.70% of the stock of Daré Bioscience is held by institutions.Read more about Daré Bioscience's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Daré Bioscience are expected to grow in the coming year, from ($0.22) to $0.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Daré Bioscience is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Daré Bioscience is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Daré Bioscience's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin AnalyticsWall Street legend who predicted 2021 tech crash issues new warningPeople around the world follow 50-year Wall Street veteran Marc Chaikin for his surprisingly accurate stock predictions. And he just issued an urgent WARNING for some of the most popular stocks in U.S. history.Watch his stock warning right here, 100% free of charge About Daré Bioscience Stock (NASDAQ:DARE)Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.Read More DARE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DARE Stock News HeadlinesMay 15 at 5:05 PM | msn.comBrookline Capital upgrades Dare Bioscience, cites improved fundingMay 15 at 5:05 PM | finance.yahoo.comQ1 2024 Dare Bioscience Inc Earnings CallMay 15 at 9:52 AM | msn.comDaré Bioscience, Inc. (NASDAQ:DARE) Q1 2024 Earnings Call TranscriptMay 15 at 4:49 AM | finance.yahoo.comDare Bioscience Inc (DARE) (Q1 2024) Earnings Call Transcript Highlights: Strategic Moves Amid ...May 14 at 8:00 AM | globenewswire.comDaré Bioscience Reports First Quarter 2024 Financial Results and Provides Company UpdateMay 13 at 9:43 AM | msn.comACA's Davis Dare, Eric Hines lead baseball team to state tournament after basketball successMay 12 at 3:00 AM | americanbankingnews.comDaré Bioscience (DARE) Scheduled to Post Earnings on TuesdayMay 10, 2024 | yahoo.comDare To Love Me: Everything to Know About Upcoming K-DramaMay 9, 2024 | yahoo.comDare To Love Me Creators Tease Kim Myung-Soo & Lee Yoo-Young’s Onscreen ChemistryMay 7, 2024 | yahoo.comScammer impersonates Dare Co. Sheriff’s deputyMay 7, 2024 | finance.yahoo.comDaré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024May 2, 2024 | globenewswire.comDaré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke NetworkMay 1, 2024 | msn.comSchool District of Philadelphia and PA Office of the Attorney General Host Dare to Dream Career WeekMay 1, 2024 | msn.comDare County man accused of fatal stabbingApril 30, 2024 | finance.yahoo.comDaré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key CatalystsApril 30, 2024 | globenewswire.comDaré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key CatalystsApril 27, 2024 | yahoo.comDare To Love Me Releases Trailer Teasing Kim Myung-Soo’s Character ArcApril 25, 2024 | yahoo.comDare To Love Me Releases Park Eun-Suk & Joe In’s Character DetailsApril 23, 2024 | globenewswire.comDaré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1April 19, 2024 | msn.comBrookline Capital Downgrades Daré Bioscience (DARE)April 11, 2024 | globenewswire.comDaré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal ContraceptiveApril 5, 2024 | yahoo.comNickelodeon 'Double Dare' host Marc Summers says 'Quiet on Set' producers blindsided himApril 5, 2024 | yahoo.comDare to dream: How Fort Worth woman brings hope to ‘communities of underprivileged’April 4, 2024 | yahoo.comThe DARE Program Tried to Reshape the Image of Police Officers in the United StatesApril 4, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: BiomX (PHGE), Daré Bioscience (DARE)See More Headlines Receive DARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today5/15/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DARE CUSIPN/A CIK1401914 Webwww.darebioscience.com Phone(858) 926-7655Fax617-494-1544Employees23Year FoundedN/APrice Target and Rating Average Stock Price Target$4.50 High Stock Price Target$6.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,150.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,160,000.00 Net MarginsN/A Pretax Margin-1,074.11% Return on Equity-1,482.38% Return on Assets-120.75% Debt Debt-to-Equity RatioN/A Current Ratio0.86 Quick Ratio0.86 Sales & Book Value Annual Sales$2.81 million Price / Sales12.89 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-7.20Miscellaneous Outstanding Shares100,580,000Free Float95,251,000Market Cap$36.21 million OptionableNot Optionable Beta1.31 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMs. Sabrina Martucci Johnson (Age 57)CEO, President, Principal Financial Officer, Secretary & Director Comp: $804.07kMs. Lisa Walters-Hoffert (Age 65)Executive Officer Comp: $523.2kMr. Mark Walters (Age 69)Vice President of Operations Ms. MarDee J. Haring-Layton (Age 48)Chief Accounting Officer Dr. David FriendChief Scientific OfficerKey CompetitorsApollomicsNASDAQ:APLMImmunoPrecise AntibodiesNASDAQ:IPAViracta TherapeuticsNASDAQ:VIRXAprea TherapeuticsNASDAQ:APREAcurx PharmaceuticalsNASDAQ:ACXPView All Competitors DARE Stock Analysis - Frequently Asked Questions Should I buy or sell Daré Bioscience stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Daré Bioscience in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DARE shares. View DARE analyst ratings or view top-rated stocks. What is Daré Bioscience's stock price target for 2024? 3 brokerages have issued 12 month price targets for Daré Bioscience's shares. Their DARE share price targets range from $3.00 to $6.00. On average, they predict the company's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 1,150.0% from the stock's current price. View analysts price targets for DARE or view top-rated stocks among Wall Street analysts. How have DARE shares performed in 2024? Daré Bioscience's stock was trading at $0.3090 at the beginning of 2024. Since then, DARE stock has increased by 16.5% and is now trading at $0.36. View the best growth stocks for 2024 here. When is Daré Bioscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our DARE earnings forecast. How were Daré Bioscience's earnings last quarter? Daré Bioscience, Inc. (NASDAQ:DARE) announced its earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.01. The biotechnology company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.52 million. During the same quarter in the previous year, the company earned ($0.09) earnings per share. What other stocks do shareholders of Daré Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Daré Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Matinas BioPharma (MTNB), Novavax (NVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE). Who are Daré Bioscience's major shareholders? Daré Bioscience's stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Daré Bioscience? Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DARE) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAmazon's betting big on this unknown AI companyManward PressWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingProtect Your Bank Account Before It’s Too LateWeiss RatingsGold Set to EXPLODE!Gold Safe Exchange"The Biggest Drug Ever" Is ComingBehind the MarketsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daré Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
